Consensus nomenclature for radionuclide therapy : initial recommendations from nuclear medicine global initiative
Al-Ibraheem, Akram Scott, Andrew M Abdlkadir, Ahmed Saad Vrachimis, Alexis Lamoureux, Francois Trujillo, Patricia Bernal Bailey, Dale L More, Stuart Giammarile, Francesco Kumar, Rakesh
Al-Ibraheem, Akram
Scott, Andrew M
Abdlkadir, Ahmed Saad
Vrachimis, Alexis
Lamoureux, Francois
Trujillo, Patricia Bernal
Bailey, Dale L
More, Stuart
Giammarile, Francesco
Kumar, Rakesh
Citations
Altmetric:
Affiliation
King Hussein Cancer Center; University of Jordan; Austin Health; Sandwell and West Birmingham NHS Trust; et al.
Other Contributors
Publication date
2025-03-27
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Since its inception in 2012, the Nuclear Medicine Global Initiative (NMGI) of the Society of Nuclear Medicine and Molecular Imaging has played an important role in addressing significant challenges in the field of nuclear medicine and molecular imaging. The first 3 projects were dedicated to standardizing pediatric nuclear medicine practices, addressing the global challenges of radionuclide access and availability, and assessing the educational and training initiatives on theranostics across the globe. These efforts aimed to advance human health, foster worldwide educational collaboration, and standardize procedural guidelines to enhance quality and safety in nuclear medicine practice. In its latest project, NMGI aimed to develop a unified nomenclature for systemic radionuclide therapy in nuclear medicine, addressing the diverse terminology currently used. An online survey was distributed to NMGI member organizations, drawing participation from various geographical locations and disciplines. The survey anonymously collected responses from physicians, physicists, scientists, radiopharmacists, radiopharmaceutical scientists, dosimetrists, technologists, and nurse managers, totaling 240 responses from 30 countries. Findings revealed a prevailing use of the term targeted radionuclide therapy for radionuclide therapy, with 52% of respondents expressing a preference for this term. In contrast, approximately 37% favored "radiopharmaceutical therapy," whereas 11% favored "molecular radionuclide therapy." Other key terms under the umbrella of targeted radionuclide therapy were also discussed to achieve a consensus on terminology. NMGI efforts to standardize terminology in this dynamic and fluid field should improve communication within the field, better reflect the technology used, enable comparison of results, and ultimately lead to improved patient outcomes.
Citation
Al-Ibraheem A, Scott AM, Abdlkadir AS, Vrachimis A, Lamoureux F, Trujillo PB, Bailey DL, More S, Giammarile F, Kumar R, Nonnekens J, Cutler CS, Urbain JC, Dibble EH, Sathekge MM, Bomanji J, Cerci JJ, Thomas E, Small W, Louw L, O JH, Ting Lee S, Nadel H, Jacene H, Watabe T, Hee-Seung Bom H, Bouyoucef SE, Weston C, Wadsley J, Irwin AG, Croasdale J, Zanzonico P, Paez D, Ghesani M. Consensus Nomenclature for Radionuclide Therapy: Initial Recommendations from Nuclear Medicine Global Initiative. J Nucl Med. 2025 Mar 27:jnumed.124.269215. doi: 10.2967/jnumed.124.269215. Epub ahead of print
Type
Article